RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye

* wall-street.cz is not responsible for the content in this press release. RNAi je technologie, které patří zajisté budoucnost a možnost de facto přímo ovlivňovat nejrůznější pochody v lidském těle. Avšak, je to, jako byste měli klíče od továrny, kde vidíte všechny procesy, u nichž neznáte přesně kauzality, víte jich dost, ale pořád je to mizivě málo a další …

Continue reading ‘RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye’ »

RXi Pharmaceuticals Presented Promising New Data with Self-delivering RNAi Compounds Targeting Tyrosinase and Collagenase

* wall-street.cz is not responsible for the content in this press release. RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology, presented new data, on Saturday, May 9, 2015, on the Company’s proprietary self-delivering RNAi ) compounds developed to target Tyrosinase …

Continue reading ‘RXi Pharmaceuticals Presented Promising New Data with Self-delivering RNAi Compounds Targeting Tyrosinase and Collagenase’ »

RXi Pharmaceuticals Receives Orphan Drug Designation for Samcyprone™ from the U.S. FDA for the Treatment of Malignant Melanoma Stage IIb to IV

* wall-street.cz is not responsible for the content in this press release. Rxi se stále potácí před „bankrotem“ po spekulativním obchodu hlavních věřitelů, jimž se společnost stala pouze výtahem pro vlastní firmy ve zcela jiném odvětví medicíny. Tato nová prohlášení Rxi jsou tak pouze vějičkami pro případné nové public investory. Předpokládám delisting z NASDAQ a návrat firmy …

Continue reading ‘RXi Pharmaceuticals Receives Orphan Drug Designation for Samcyprone™ from the U.S. FDA for the Treatment of Malignant Melanoma Stage IIb to IV’ »

RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi’s Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer

* wall-street.cz is not responsible for the content in this press release.  RXi Pharmaceuticals Corporation (NASDAQ: RXII) and privately-held MirImmune LLC, today announced that they have entered into an exclusive license agreement to RXi’s novel and proprietary sd-rxRNA® technology for use in developing innovative cell-based cancer immunotherapies. The collaboration has the potential to result in novel, …

Continue reading ‘RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi’s Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer’ »

Rxi Pharmaceuticals(RXII) opustili hlavní držitelé prioritních akcií Tang a RTW za podivných okolností

Pravděpodobně jim tak RXII posloužila jako letadlo pro vlastní společnost LJPC (La Jola Pharmaceuticals), kde je Tang i ředitelem. Není tajemstvím, že v případě RTW se jedná o fond jeho syna. Oba pak obdrželi při vzniku společnosti RXII obrovské procento prioritních akcií, se zřejmým budoucím účelem  prodeje na otevřeném trhu s velkým ziskem na úkor všech ostatních …

Continue reading ‘Rxi Pharmaceuticals(RXII) opustili hlavní držitelé prioritních akcií Tang a RTW za podivných okolností’ »

RXi Pharmaceuticals Expands its Clinical Pipeline with an Exclusive Global License for a Second Phase 2 Clinical Compound

* wall-street.cz is not responsible for the content in this press release.  RXi Pharmaceuticals Corporation (RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it has entered into an assignment and exclusive global license agreement with Hapten Pharmaceuticals, LLC for the …

Continue reading ‘RXi Pharmaceuticals Expands its Clinical Pipeline with an Exclusive Global License for a Second Phase 2 Clinical Compound’ »

RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

* wall-street.cz is not responsible for the content in this press release.  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced completion of enrollment in its first Phase 2a study, RXI-109-1301.  The preliminary results from the 3-month observations confirmed …

Continue reading ‘RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301’ »